160 related articles for article (PubMed ID: 23977976)
1. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
[TBL] [Abstract][Full Text] [Related]
2. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
[TBL] [Abstract][Full Text] [Related]
3. Regulation of health-related technologies in Germany.
Perleth M; Busse R; Schwartz FW
Health Policy; 1999 Jan; 46(2):105-26. PubMed ID: 10346284
[TBL] [Abstract][Full Text] [Related]
4. Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective.
Cookson R; Hutton J
Health Policy; 2003 Feb; 63(2):167-78. PubMed ID: 12543529
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Thatte U; Hussain S; de Rosas-Valera M; Malik MA
Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
[TBL] [Abstract][Full Text] [Related]
7. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
Wallerstedt SM; Henriksson M
Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
[TBL] [Abstract][Full Text] [Related]
8. Regulating biotechnology: a rational-political model of policy development.
Wiktorowicz M; Deber R
Health Policy; 1997 May; 40(2):115-38. PubMed ID: 10167067
[TBL] [Abstract][Full Text] [Related]
9. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
10. Apples, oranges, forests, and trees.
Cushman R
J Health Polit Policy Law; 1999 Aug; 24(4):763-8. PubMed ID: 10503157
[No Abstract] [Full Text] [Related]
11. US 21st Century Cures Act secures health-care research funding.
Furlow B
Lancet Oncol; 2017 Jan; 18(1):24. PubMed ID: 27979600
[No Abstract] [Full Text] [Related]
12. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
Bae EY; Lee EK
Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
[TBL] [Abstract][Full Text] [Related]
13. Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?
Tarricone R; Torbica A; Ferré F; Drummond M
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):707-18. PubMed ID: 25196848
[TBL] [Abstract][Full Text] [Related]
14. Some personal reflections on health care reform.
Shader RI
J Clin Psychopharmacol; 2008 Dec; 28(6):599-600. PubMed ID: 19011426
[No Abstract] [Full Text] [Related]
15. Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.
McCabe C; Claxton K; O'Hagan A
Int J Technol Assess Health Care; 2008; 24(2):140-5. PubMed ID: 18400115
[TBL] [Abstract][Full Text] [Related]
16. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
17. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
Hutton J; Trueman P; Facey K
Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
[TBL] [Abstract][Full Text] [Related]
18. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
19. Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities.
Henshall C; Mardhani-Bayne L; Frønsdal KB; Klemp M
Int J Technol Assess Health Care; 2011 Jul; 27(3):253-60. PubMed ID: 21756413
[TBL] [Abstract][Full Text] [Related]
20. A limitation to equal access in clinical trials: the Medicare review process.
King SB; Kandzari DE
JACC Cardiovasc Interv; 2013 Jun; 6(6):640-1. PubMed ID: 23787242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
